BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11785842)

  • 1. Dendritic cells for the induction of EBV immunity.
    Subklewe M
    Recent Results Cancer Res; 2002; 159():38-43. PubMed ID: 11785842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
    Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
    PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
    Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
    J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Front Immunol; 2023; 14():878953. PubMed ID: 37033971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
    Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
    Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
    Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
    Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
    Rancan C; Schirrmann L; Hüls C; Zeidler R; Moosmann A
    PLoS Pathog; 2015 Jun; 11(6):e1004906. PubMed ID: 26067064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
    Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [T cells recognizing EBV-epitopes arose in co-culture of peripheral blood mononuclear cells from EB-infected patients and dendritic cells loaded with LMP2-mixed peptides].
    Xing YP; Cen XN; Tong CR; Gu JY; Cai P; Tao XY; Jin X; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):392-6. PubMed ID: 18426672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
    Sun H; Yao K; Chen Y; Zhou F
    Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting roles of dendritic cells and B cells in the immune control of Epstein-Barr virus.
    Bickham K; Münz C
    Curr Top Microbiol Immunol; 2003; 276():55-76. PubMed ID: 12797443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus induces the differentiation of semi-mature dendritic cells from cord blood monocytes.
    Jin YY; Wang X; Du J; Cao RM; Law HK; Wang JJ; Chen TX
    Hum Immunol; 2014 Apr; 75(4):306-16. PubMed ID: 24530751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.
    Subklewe M; Chahroudi A; Bickham K; Larsson M; Kurilla MG; Bhardwaj N; Steinman RM
    Eur J Immunol; 1999 Dec; 29(12):3995-4001. PubMed ID: 10602009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
    Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
    Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.